Idorsia (LTS:0RQE) EBIT

: CHF-347.5 Mil (TTM As of Sep. 2023)

View and export this data going back to 2017. Start your Free Trial

Idorsia's earnings before interest and taxes (EBIT) for the three months ended in Sep. 2023 was CHF230.4 Mil. Its earnings before interest and taxes (EBIT) for the trailing twelve months (TTM) ended in Sep. 2023 was CHF-347.5 Mil.

EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition. Idorsia's annualized ROC % for the quarter that ended in Sep. 2023 was -41.24%. Idorsia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was 398.18%.

EBIT is also linked to Joel Greenblatt's definition of earnings yield. Idorsia's Earnings Yield (Joel Greenblatt) % for the quarter that ended in Sep. 2023 was -26.79%.

Idorsia EBIT Historical Data

The historical data trend for Idorsia's EBIT can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Idorsia Annual Data

Trend

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

EBIT

Get a 7-Day Free Trial

-371.08

-476.63

-439.56

-606.87

-802.92

Idorsia Quarterly Data
	Dec18	Mar19	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23
EBIT	Get a 7-Day Free Trial															-209.28	-185.38	-206.38	-186.19	230.44

Competitive Comparison

For the Biotechnology subindustry, Idorsia's EV-to-EBIT, along with its competitors' market caps and EV-to-EBIT data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Idorsia EV-to-EBIT Distribution

For the Biotechnology industry and Healthcare sector, Idorsia's EV-to-EBIT distribution charts can be found below:

* The bar in red indicates where Idorsia's EV-to-EBIT falls into.

Idorsia EBIT Calculation

EBIT, sometimes also called Earnings Before Interest and Taxes, is a measure of a firm's profit that includes all expenses except interest and income tax expenses. It is the difference between operating revenues and operating expenses. When a firm does not have non-operating income, then Operating Income is sometimes used as a synonym for EBIT and operating profit.

EBIT for the trailing twelve months (TTM) ended in Sep. 2023 adds up the quarterly data reported by the company within the most recent 12 months, which was CHF-347.5 Mil.

Idorsia (LTS:0RQE) EBIT Explanation

1. EBIT or Operating Income is linked to Return on Capital for both regular definition and Joel Greenblatt's definition.

Idorsia's annualized ROC % for the quarter that ended in Sep. 2023 is calculated as:

	ROC % (Q: Sep. 2023 )
=	NOPAT	/	Average Invested Capital
=	Operating Income * ( 1 - Tax Rate % )	/	( (Invested Capital (Q: Jun. 2023 )	+	Invested Capital (Q: Sep. 2023 ))	/ count )
=	-213.48 * ( 1 - 0.62% )	/	( (459.183	+	569.603)	/ 2 )
=	-212.156424	/	514.393
=	-41.24 %

where

	Invested Capital		(Q: Jun. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	527.763	-	24.795	-	( 43.785	-	max(0, 193.488	-	240.654	+	43.785	))
=	459.183

	Invested Capital		(Q: Sep. 2023 )
=	Total Assets	-	Accounts Payable & Accrued Expense	-	Excess Cash
=	Total Assets	-	Accounts Payable & Accrued Expense	-	( Cash, Cash Equivalents, Marketable Securities	-	max(0, Total Current Liabilities	-	Total Current Assets	+	Cash, Cash Equivalents, Marketable Securities	))
=	653.12	-	18.372	-	( 266.13	-	max(0, 311.084	-	376.229	+	266.13	))
=	569.603

Note: The Operating Income data used here is four times the quarterly (Sep. 2023) data.

2. Joel Greenblatt's definition of Return on Capital:

Idorsia's annualized ROC (Joel Greenblatt) % for the quarter that ended in Sep. 2023 is calculated as:

	ROC (Joel Greenblatt) %		(Q: Sep. 2023 )
=	EBIT	/	Average of (Net fixed Assets	+	Net Working Capital)
=	EBIT	/	Average of (Property, Plant and Equipment	+	Net Working Capital)
			Q: Jun. 2023		Q: Sep. 2023
=	EBIT	/	( ( (Property, Plant and Equipment + Net Working Capital)	+	(Property, Plant and Equipment + Net Working Capital) )	/	count )
=	921.772	/	( ( (219.765 + max(27.929, 0))	+	(212.293 + max(3.003, 0)) )	/	2 )
=	921.772	/	( ( 247.694	+	215.296 )	/	2 )
=	921.772	/	231.495
=	398.18 %

where Working Capital is:

	Working Capital		(Q: Jun. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(21.225	+	54.548	+	109.416)	-	(24.795	+	0	+	132.465)
=	27.929

	Working Capital		(Q: Sep. 2023 )
=	(Accounts Receivable	+	Total Inventories	+	Other Current Assets)	-	(Accounts Payable & Accrued Expense	+	Defer. Rev.	+	Other Current Liabilities)
=	(24.4	+	60.331	+	23.348)	-	(18.372	+	0	+	86.704)
=	3.003

When net working capital is negative, 0 is used.

Note: The EBIT data used here is four times the quarterly (Sep. 2023) EBIT data.

3. It is also linked to Joel Greenblatt's definition of Earnings Yield:

Idorsia's Earnings Yield (Joel Greenblatt) % for today is calculated as:

Earnings Yield (Joel Greenblatt) %	=	EBIT (TTM)	/	Enterprise Value (Q: Sep. 2023 )
	=	-347.504	/	1297.026
	=	-26.79 %

Idorsia EBIT Related Terms

Thank you for viewing the detailed overview of Idorsia's EBIT provided by GuruFocus.com. Please click on the following links to see related term pages.

Idorsia (LTS:0RQE) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Idorsia Ltd (LTS:0RQE) » Definitions » EBIT

Comparable Companies

Traded in Other Exchanges

IDRSF:USA IDIAz:UK IDIA:Switzerland

Address

Hegenheimermattweg 91, Allschwil, CHE, 4123

Website

https://www.idorsia.com

Idorsia Ltd is a biopharmaceutical company engaged in discovering, developing, and commercializing of medicines for unmet medical needs. It is a biotech hub of Europe specialized in the discovery and development of small molecules, to provide innovative therapeutic options. The company focuses on multiple therapeutic areas which include the central nervous system, cardiovascular disorders, immunological disorders, and orphan diseases. Idorsia's development compounds target a number of different diseases such as Resistant Hypertension, lupus, insomnia, Cerebral vasospasm, and Fabry disease. Geographically, it derives revenue from Switzerland.

Idorsia (LTS:0RQE) Headlines

No Headlines